Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2011-04-19
2011-04-19
Jones, D L (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S001110, C424S001650, C424S001690, C424S009300, C424S009360, C534S015000
Reexamination Certificate
active
07927581
ABSTRACT:
Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.
REFERENCES:
patent: 4622420 (1986-11-01), Meares et al.
patent: 4659839 (1987-04-01), Nicolotti et al.
patent: 4678667 (1987-07-01), Meares et al.
patent: 4831175 (1989-05-01), Gansow et al.
patent: 4880008 (1989-11-01), Lauffer
patent: 4897255 (1990-01-01), Fritzberg et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5099069 (1992-03-01), Gansow et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5246692 (1993-09-01), Gansow et al.
patent: 5492892 (1996-02-01), Andersen et al.
patent: 5637759 (1997-06-01), Hearst et al.
patent: 5641878 (1997-06-01), Dandliker et al.
patent: 5705143 (1998-01-01), Bower et al.
patent: 5891418 (1999-04-01), Sharma
patent: 6001809 (1999-12-01), Thorsett et al.
patent: 6207858 (2001-03-01), Chinn et al.
patent: 6342598 (2002-01-01), Anelli et al.
patent: 6517814 (2003-02-01), Liu
patent: 6652834 (2003-11-01), Anelli et al.
patent: 6656448 (2003-12-01), Carpenter et al.
patent: 6991775 (2006-01-01), Koerner et al.
patent: 7238341 (2007-07-01), Zhang et al.
patent: 329 363 (1989-02-01), None
patent: 0 882 454 (1998-12-01), None
patent: 0 515 313 (2000-08-01), None
patent: WO 90/12050 (1990-10-01), None
patent: WO 93/17719 (1993-09-01), None
patent: WO 95/19187 (1995-07-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/23524 (1996-08-01), None
patent: WO 96/23526 (1996-08-01), None
patent: WO 96/36361 (1996-11-01), None
patent: WO 97/13490 (1997-04-01), None
patent: WO 97/14804 (1997-04-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 01/08712 (2001-02-01), None
patent: WO 01/09188 (2001-02-01), None
patent: WO 01/25410 (2001-04-01), None
patent: WO 01/30398 (2001-05-01), None
U.S. Appl. No. 08/875,365, filed Dec. 12, 1997.
Aime et al., “Synthesis, Characterization, and 1/T1NMRD Profiles of Gadolinium(III) Complexes of Monoamide Derivatives of DOTA-like Ligands, X-ray Structure of the 10-[2-[[2-Hydroxy-1-(hydroxymethyl)ethyl]amino]-1-[(phenylmethoxy)methyl]-2-oxo-ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic Acid-Gadolinium(III) Complex,”Inorg. Chem., 1992, 31:2422-2428.
Aime et al., “Multinuclear and multifrequency NMR study of gadolinium(III) complexes with bis-amide derivaties of ethylenedioxydiethylene-dinitrilotetraacetic acid,”J. Chem. Soc. Dalton Trans., 2000, pp. 3435-3440.
Alavi et al., “Radiolabeled Antifibrin Antibody in the Detection of Venous Thrombosis: Preliminary Results,”Radiology, 1990, 175:79-85.
Alexander et al., “Intracranial Black-Blood MR Angiography with High-Resolution 3D Fast Spin Echo,”Magnetic Resonance in Medicine, 1998, 40(2):298-310.
Amedio Jr. et al., “A Practical Manufacturing Synthesis of 1-(R)-Hydroxymethyl-DTPA: An Important Intermediate in the Synthesis of MRI Contrast Agents,”Synthetic Communications, 1999, 29(14):2377-2391.
Amedio Jr. et al., “Preparation of N,N-BIS[2-[N′, N′-BBIS (Tert-Butoxycarbonyl)Methyl]-Amino]Ethyl-L-Aspartic Acid: An Intermediate in the Synthesis of MRI Contrast Agents,”Synthetic Communications, 2000, 30(20):3755-3763.
Augustijns et al., “Peptidyl Dipeptidase A-Catalyzed Metabolism of Delta Sleep-Inducing Peptide in Bovine Brain Microvessel Endothelial Cells: A Cell Culture Model of the Blood Brain Barrier,”Biochem. Biophys. Res. Comm., 1995, 210(3):987-994.
Bakker et al., “In Vivo Application of [111In-DTPA-D-PHE1]-Octreotide for Detection of Somatostatin Receptor-Positive Tumors in Rats,”Life Sciences, 1991, 49:1593-1601.
Bautovich et al., “Detection of Deep Venous Thrombi and Pulmonary Embolus with Technetium-99m-DD-3B6/22 Anti-fibrin Monoclonal Antibody Fab' Fragment,”J. Nucl. Med., 1994, 35:195-202.
Bligh et al., “Neutral Gadolinium(III) Complexes of Bulky Octadentate dtpa Derivatives as Potential Contrast Agents for Magnetic Resonance Imaging,”Polyhedron, 1995, 14(4)567-569.
Bulte et al., “Dysproium-DOTA-PAMAM Dendrimers as Macromolecular T2 Contrast Agents,”Invest. Radiol., 1998, 33(11):841-845.
Caravan et al., “Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications,”Chem. Rev., 1999, 99:2293-2352.
Collen et al., “Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis,”J. Clin. Invest., 1983, 71:368-376.
Deacon et al., “Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo,”J. Clin. Endocrinol., 1995, 80(3):952-957.
Edelman et al., “Extracranial Carotid Arteries: Evaluation with “Black Blood” MR Angiography,”Radiology, 1990, 177(1):45-50.
Harker et al., “Role of Platelets and Thrombosis in Mechanisms of Acute Occlusion and Restenosis After Angioplasty,”Am. J. Cardiology, 1987, 60:20B-28B.
Hermans et al., “Fibrin: Structure and Interactions,”Semin. Thromb. Hemost., 1982, 8:11-24.
Kakkar et al., “I-Labelled Fibrinogen Test Adapted for Routine Screening for Deep-Vein Thrombosis,”Lancet, 1970, 1:540-542.
Kellar et al., “Magnetic Field Dependence of Solvent Proton Relaxation by Solute Dysprosium(III) Complexes,”Invest. Radiol., 1998, 33(11):835-840.
Knight et al., “Fragment E1Labeled with I-123 in the Detection of Venous Thrombosis,”Radiology, 1985, 156:509-514.
Kojima et al., “Bioimaging of Nitric Oxide with Fluorescent Indicators Based on the Rhodamine Chromophore,”Anal. Chem., 2001, 73:1967-1973.
Kolc, “Amino Acids and Peptides LXXXIX. Synthesis ofL-4-Azalysine,D-4-Azalysine, andL-4-Analysine-[6-14C],”Coll. Czech. Chem. Commun., 1969, 34:630-634.
Konings et al., “Gadolinium Complexation by a New DTPA-Amide Ligand. Amide Oxygen Coordination,”Inorg. Chem., 1990, 29:1488-1491.
Krieter et al., “In Vivo Metabolism of Atrial Natriuretic Peptide: Identification of Plasma Metabolites and Enzymes Responsible for Their Generation,”J. Pharmacol. Exp. Ther., 1989, 249(2):411-417.
Lanza et al., “High-Frequency Ultrasonic Detection of Thrombi with A Targeted Contrast System,”Ultrasound in Med.&Bio., 1997, 23(6):863-870.
Lauffer, “Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging: Theory and Design,”Chem. Rev., 1987, 87:901-927.
Liu et al., “Labeling a Hydrazino Nicotinamide-Modified Cyclic Iib/IIIa Receptor Antagonist with99mTc Using Aminocaroboxylates as Coligands,”Bioconjugate Chem., 1996, 7:63-71.
Martin et al., “Gadolinium(III) Di- and Tetrachelates Designed for in Vivo Noncovalent Complexation with Plasma Proteins: A Novel Molecular Design for Blood Pool MRI Contrast Enhancing Agents,”Bioconjugate Chem., 1995, 6:616-623.
Moskowitz and Budzynski, “The (DD)E Complex is Maintained by A Composite Fibrin Polymerization Site,”Biochemistry, 1994, 33:12937-12944.
Mühler and Hochhaus, “Metabolism of Dynorphin A 1-13 in Human Blood and Plasma,”Pharm. Res.1995, 12(8):1165-1170.
Mühler et al., “Interspecies comparison of in vitro plasma degradation of dynorphin A 1-13,”Pharmazie, 1996, 51(8):581-585.
Muller et al., “Physicochemical Characterization of MS-325, a New Gadolinium Complex, by Multinuclear Relaxometry,”Eur. J. Inorg. Chem., 1999, pp. 1949-1955.
Mühler et al., “Assessment of Complex Peptide Degradation Pathways via Structured Multicompartmental Modeling Approaches: The Metabolisn of Dynorphin A1-13 and Related Fragments in Human Plasma,”J. Pharm. Sci., 1999, 88(9):938-944.
Murphey et al., “Metabolism of Bradykinin in Vivo in Humans: Identification of BK1-5 as a Stable Plasma Peptide Metabolite,”J. Pharmacol. Exp. Ther., 2000, 294:263-269.
Murru et al.,“Luminescence Behaviour o
Amedio John C.
Caravan Peter D.
Dumas Stephane
Kolodziej Andrew
McMurry Thomas J.
Factor 1A, LLC
Fish & Richardson P.C.
Jones D L
LandOfFree
Peptide-based multimeric targeted contrast agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide-based multimeric targeted contrast agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide-based multimeric targeted contrast agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2714286